SCHEMBL26501318

SCHEMBL26501318

CC(C)OC1CCN(CCCCCCCCCC(=O)N2CCN(C(=O)CC(C)(C)C)CC2)C1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GNAI3 P08754 6/20 0.36
GNAI1 P63096 6/20 0.36
GNAO1 P09471 5/20 0.36
KCNQ3 O43525 1/20 0.35
KCNQ2 O43526 1/20 0.35
TPSAB1 Q15661 1/20 0.34
TPSD1 Q9BZJ3 1/20 0.34
TPSG1 Q9NRR2 1/20 0.34
HTR7 P34969 4/20 0.34
HTR1A P08908 3/20 0.34
PDCD1 Q15116 1/20 0.34
CD274 Q9NZQ7 1/20 0.34
CHRM2 P08172 2/20 0.33
CHRM4 P08173 2/20 0.33
CHRM5 P08912 2/20 0.33
CHRM1 P11229 2/20 0.33
CHRM3 P20309 2/20 0.33
NPC1 O15118 2/20 0.33
DRD2 P14416 2/20 0.32
MLNR O43193 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26501320 1.00 GNAI3 (0.36) GNAI3GNAI1GNAO1KCNQ3KCNQ2
SCHEMBL26505142 0.85 GNAI3 (0.39) GNAI3GNAI1GNAO1TPSAB1TPSD1
SCHEMBL26501276 0.81 CHRM3 (0.35) KCNQ3KCNQ2HTR1ACHRM2CHRM4
SCHEMBL26501275 0.78 PAOX (0.35) HTR7HTR1ACHRM2CHRM4CHRM5
SCHEMBL26501277 0.78 PAOX (0.35) HTR7HTR1ACHRM2CHRM4CHRM5
SCHEMBL26501314 0.77 HRH2 (0.42) HTR7HTR1ADRD2HRH2HRH1
SCHEMBL26742318 0.76 NPC1 (0.51) GNAI3GNAI1GNAO1CHRM2CHRM4
SCHEMBL26501345 0.72 GBA1 (0.35) GNAI3GNAI1GNAO1
SCHEMBL24942994 0.72 ITGB3 (0.43) GNAI3GNAI1GNAO1NPC1
SCHEMBL26302335 0.72 GNAI3 (0.54) GNAI3GNAI1GNAO1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230321253-A1 BIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL USES THEREOF Risen (Suzhou) Pharma Tech Co., Ltd. (CN) 2023-10-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230321253-A1 BIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL USES THEREOF KRAS, MDM2, NRAS GNAI3 271/4885GNAI1 219/4885GNAO1 1163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.